|
Interaction as determined by means of checkerboard assay |
|||
| Combination |
Nr of MRSA strains (%) for which combinations gave |
||
|
|
|||
| Synergy |
No interaction |
Antagonism |
|
|
|
|||
| LVX + VA (n = 50) |
16 (32) |
34 (68) |
0 |
| LVX + TEC (n = 50) |
9 (18) |
41 (82) |
0 |
| CTX + VA (n = 50) |
23 (46) |
27 (54) |
0 |
| CTX + TEC (n = 50) |
43 (86) |
7 (14) |
0 |
| LVX + VA + AMK (n = 25) |
5 (20) |
20 (80) |
0 |
| LVX + TEC + AMK (n = 25) |
10 (40) |
15 (60) |
0 |
| LVX + VA + CAZ (n = 25) |
15 (60) |
10 (40) |
0 |
| LVX + TEC + CAZ (n = 25) |
20 (80) |
5 (20) |
0 |
| LVX + VA + FEP (n = 25) |
10 (40) |
15 (60) |
0 |
| LVX + TEC + FEP (n = 25) |
10 (40) |
15 (60) |
0 |
| LVX + VA + IPM (n = 25) |
5 (20) |
20 (80) |
0 |
| LVX + TEC + IPM (n = 25) |
10 (40) |
15 (60) |
0 |
| LVX + VA + TZP (n = 25) |
5 (20) |
20 (80) |
0 |
| LVX + TEC + TZP (n = 25) |
20 (80) |
5 (20) |
0 |
|
LVX: levofloxacin; VA: vancomycin; TEC: teicoplanin; CTX: cefotaxime; AMK: amikacin; CAZ: ceftazidime; FEP: cefepime; IPM: imipenem; TZP: piperacillin/tazobactam. | |||
Drago et al. BMC Infectious Diseases 2007 7:111 doi:10.1186/1471-2334-7-111 |
|||